Senegal

in page functions
[French]
Senegal
Total population (2018) 16,524,421
Birth cohort (2018) 587,285
Surviving Infants (surviving to 1 year per year, 2018) 568,146
Infant mortality rate (deaths < 1 year per 1000 births, 2015) 42/1000
Child mortality rate (deaths < 5 years per 1000 births, 2015) 47/1000
World Bank Index, IDA (2015) 3.82
Gross Nation Income (per capita US$, 2015) 980
Co-financing group (2018) Initial self-financing
No. of districts/territories (2017) 76

Contact Gavi

For more info, contact Gavi country representative officer or email here

Gavi support for Senegal

Type of support

Approvals

2001-2022 (US$)
(20 Jul 2018)

Commitments

2001-2022 (US$)
(20 Jul 2018)

Disbursements

2000-2018 (US$)
(20 Jul 2018)

% Disbursed

(20 Jul 2018)
2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 2018 2019
Total $129,888,489 $143,125,967 $132,022,065
Cash Support (CASHSUPP) $145,000 $170,000 $145,000 100%
Cold Chain Equipment Optimisation Platform (CCEOP) $2,460,998 $2,460,998
Health system strengthening (HSS 1) $3,585,500 $3,585,500 $3,585,500 100%
Health system strengthening (HSS 2) $11,322,521 $13,882,499 $6,578,863 58%
HepB mono (NVS) $588,743 $588,743 $588,743 100%
HPV (NVS) $1,896,500 $3,463,500 $1,549,500 82%
HPV Demo (NVS) $202,271 $202,271 $202,271 100%
HPV MAC (NVS) $8,486,500 N/A
HPV MAC - Op costs (OPC) $578,500 N/A
Immunisation services support (ISS) $2,605,740 $2,605,740 $2,605,740 100%
Injection Safety Devices (NVS) $586,500 $607,000 $731,252 125%
Injection safety support (INS) $619,474 $619,474 $619,474 100%
IPV (NVS) $2,666,332 $2,666,332 $2,454,752 92%
Measles (NVS) $579,155 $579,155 $432,326 75%
Measles-Rubella (NVS) $4,495,177 $4,495,177 $4,495,177 100%
Meningitis A - campaign (NVS) $2,670,736 $2,670,736 $2,670,736 100%
Meningitis A - operational costs (OPC) $2,567,107 $2,567,107 $2,567,107 100%
MR - Operational costs (OPC) $4,158,500 $4,158,500 $4,158,500 100%
MR-Follow-up campaign (NVS) $1,655,661 $1,655,661 $1,655,661 100%
MR-Follow-up campaign op.costs (OPC) $1,568,884 $1,568,884 $1,568,884 100%
Penta (NVS) $43,338,263 $43,338,263 $43,058,680 99%
Pneumo (NVS) $30,798,444 $30,798,444 $40,917,572 133%
Product Switch Grant (PSG) $144,445 $144,445
Rotavirus (NVS) $8,558,538 $8,558,538 $8,762,437 102%
Vaccine Introduction Grant (VIG) $2,674,000 $2,674,000 $2,673,890 100%

Red line on table indicates duration of support based on commitments.
Commitments: Multi-year programme budgets endorsed in principle by the Gavi Board. These become financial commitments upon approval each year for the following calendar year.
Approvals: Total Approved for funding

Download data for commitments, approvals & disbursements in XLS format

Senegal DTP3 / immunisation coverage

DTP3 - WHO/UNICEF estimates (2017)

Grade of confidence


N/A
DTP3 - Official country estimates (2017) 93%
M:F sex ratio at birth (2018) 1.04
Household survey: DTP3 coverage for male (2013) 89.10%
Household survey: DTP3 coverage for female (2013) 89.60%
Household survey: Last DTP3 survey (2013) 89%
% districts achieving > 80% DTP3 coverage (2017) 84%
% districts achieving < 50% DTP3 coverage (2017) 0%
MCV WHO/UNICEF estimates (2017) 90%

Breakdown of support

Non-vaccine support Vaccine support
19% 81%
$24,502,958 $107,519,107

Data refers to disbursed values, date as per above chart

Move mouse over graph for details

News and updates relating to Senegal

19 May 2018

Kenya HPV

Gavi welcomes call for coordinated global action against cervical cancer

Alliance pledges to continue support for vaccines.

07 March 2018

Female vaccine heroes: two health workers, two scientists, a teacher and a town crier

If you know something about global health, you’ve probably heard of Edward Jenner or Jonas Salk, but what about the women who also helped lay the foundations for modern immunisation? Meet five remarkable women who pushed forward the frontiers of science.

02 February 2018

Senegal - Anuradha's blog

From adolescence to adulthood: collaborating for the future of global health

On World Cancer Day 2018, Gavi's Deputy CEO Anuradha Gupta looks at how focussing on adolescent health now could help prevent cancer and other non-communicable diseases for generations to come.

close icon

modal window here